Search Results

You are looking at 101 - 110 of 1,499 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Patterns of Surveillance Advanced Imaging and Serum Tumor Biomarker Testing Following Launch of the Choosing Wisely Initiative

Randy C. Miles, Christoph I. Lee, Qin Sun, Aasthaa Bansal, Gary H. Lyman, Jennifer M. Specht, Catherine R. Fedorenko, Mikael Anne Greenwood-Hickman, Scott D. Ramsey, and Janie M. Lee

. Clinical data included age at diagnosis, race, diagnosis year, family history of breast cancer, and breast cancer–specific genetic mutation status. Tumor characteristic data included AJCC stage, grade, size, and estrogen receptor (ER), progesterone receptor

Full access

Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I–III Pancreatic Adenocarcinoma

Nina N. Sanford, Todd A. Aguilera, Michael R. Folkert, Chul Ahn, Brandon A. Mahal, Herbert Zeh, Muhammad S. Beg, John Mansour, and David J. Sher

delivery of postoperative chemotherapy include clinical factors, such as patient age, extent of postoperative complications, and presence of lymph node metastases. 10 – 13 In contrast, sociodemographic characteristics influencing receipt of adjuvant

Full access

Screening Performance for Frailty Among Older Patients With Cancer: A Cross-Sectional Observational Study of Two Approaches

Toru Okuyama, Koji Sugano, Shinsuke Iida, Takashi Ishida, Shigeru Kusumoto, and Tatsuo Akechi

was taking was investigated by a review of the medical records. Table 1 Patient Demographics and Clinical Characteristics (N=106) Depression: Presence/absence of depression was assessed using the PHQ-9. 23 The PHQ-9 consists of 9

Full access

Treatment and Survival Among Patients With Colorectal Cancer in Sub-Saharan Africa: A Multicentric Population-Based Follow-Up Study

Lucia Hämmerl, Nikolaus C.S. Mezger, Tobias P. Seraphin, Walburga Yvonne Joko-Fru, Mirko Griesel, Jana Feuchtner, Franck Gnahatin, Freddy Houéhanou Rodrigue Gnangnon, Nathan Okerosi, Phoebe Mary Amulen, Rolf Hansen, Margaret Ziona Borok, Carla Carrilho, Brahima Mallé, Clausina Ahoui Apendi, Nathan G. Buziba, Edom Seife, Biying Liu, Rafael Mikolajczyk, Donald M. Parkin, Eva J. Kantelhardt, and Ahmedin Jemal

cancer. 20 All patients with stage IV CRC should receive some form of (radio-)chemotherapy, with surgical resection depending on tumor characteristics and patient condition. Radiotherapy in a single fraction is an option for surgically unresectable stage

Full access

Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial

Rongbo Lin, Sunzhi Lin, Shuitu Feng, Qingyi Wu, Jianqian Fu, Fang Wang, Hui Li, Xiaofeng Li, Gaowang Zhang, Yongzhi Yao, Min Xin, Tianyang Lai, Xia Lv, Yigui Chen, Shangwang Yang, Yubiao Lin, Lixia Hong, Zhenyu Cai, Jianfeng Wang, Gen Lin, Shaowei Lin, Shen Zhao, Jinfeng Zhu, and Cheng Huang

pain control. Median initial dosages in opioid-tolerant patients were 1 mg (IQR, 0.5–2) and 1 mg (IQR, 0.5–2) in the PCA and non-PCA groups, respectively. Baseline characteristics ( Table 1 ) were well balanced between the 2 groups, with comparable ESAS

Full access

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma

). Patient demographics and clinical characteristics are detailed in Table 1 . Of the patients, 98% were women, 78% were white, and 19.5% were black. Median age was 59.4 years (range, 50.7–67.7 years) at initiation of palbociclib treatment. Most patients (n

Full access

Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials

Antonious Hazim, Gordon Mills, Vinay Prasad, Alyson Haslam, and Emerson Y. Chen

involved CAR T-cell therapy. The most common cancer types were leukemia (16%), lung (12%), and breast (10%) ( Table 1 ). Table 1. Characteristics of Dose-Escalation Trials Of the 3,890 patients, 2,506 had both response and dose data, among whom the ORR (CR

Full access

Mental Health and Chemical Dependency Services at US Cancer Centers

Shehzad K. Niazi, Aaron Spaulding, Emily Brennan, Sarah K. Meier, Julia E. Crook, Lauren F. Cornell, Sikander Ailawadhi, Matthew M. Clark, and Teresa A. Rummans

Social Security Act) were invited to participate in the survey. The database contains information about hospital characteristics, services offered, and staffing, and responses are validated through review, comparison, and member checking by the AHA. 41

Full access

Receipt of Screening Mammography by Insured Women Diagnosed With Breast Cancer and Impact on Outcomes

Marissa B. Lawson, Christoph I. Lee, Daniel S. Hippe, Shasank Chennupati, Catherine R. Fedorenko, Kathleen E. Malone, Scott D. Ramsey, and Janie M. Lee

addition, we used the following ICD codes to identify patients with screening encounters: Z12.31, V76.11, and V76.12. Statistical Analysis We compared clinical and tumor characteristics between women diagnosed with cancer who received screening

Full access

Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma

Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung

,500 Commission on Cancer–accredited facilities. Jointly sponsored by the American College of Surgeons and American Cancer Society, it currently captures more than 70% of newly diagnosed cancers within the United States. Relevant patient characteristics, tumor